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Early Diagnostic Value of Circulating MiRNA-21 in Lung Cancer: A
Meta-Analysis
Chang Liu, Youping Deng , Leilei Wang, Yong Mei, and Rui Zhang
Abstract: To evaluate the early diagnostic value of circulating miRNA-21 in diagnosis of lung cancer, databases
such as Wan Fang, VIP, PubMed, and Elsevier were systematically searched from 2005 to 2013 to collect relevant
references in which the diagnostic value had been evaluated. The statistics were consolidated and the qualities of
the studies were classified. The data were analyzed using Meta Disc1.4 software. The diagnostic value of circulating
miRNA-21 in lung cancer was assessed by pooling sensitivity, specificity, the likelihood ratio, and the Summary
Receiver Operating Characteristic (SROC) curve. Publication biases of the studies involved were analyzed using
Stata 11.0 software. A total of 143 papers were collected of which 8 were included, which contained 600 cases and
440 controls. A heterogeneity test proved the existence of homogeneity in this study. Upon analysis using random
effects models, the weighted sensitivity was 0.68, the specificity 0.77, the positive likelihood ratio 2.84, the negative
likelihood ratio 0.40, and the SROC Area Under the Curve (AUC) was 0.8133. Further analysis by subgroup showed
that the 5 indicators mentioned above were 0.72, 0.84, 4.50, 0.27, and 0.8987, respectively, for the serum group
and 0.63, 0.70, 1.95, 0.53, and 0.7318, respectively, for the plasma group. We conclude that circulating miRNA-21
can be regarded a valuable reference in diagnosis of lung cancer. This research showed that in lung cancer the
early diagnostic value of miRNA-21 in serum was better than that in plasma.
Key words: microRNA; early diagnosis; lung cancer; meta-analysis

1

Introduction

Lung cancer is one of the malignant tumor diseases that
threaten human health in modern society. The incidence
and mortality rate of lung cancer rank first among
various cancers across the world[1] . Once diagnosed,
lung cancer often reaches the terminal stage rapidly, and
thus patients lose the best treatment time. At present,
the gold standard for diagnosing lung cancer definitely
is still pathological diagnosis in clinics. Chest X-ray and
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CT scanning are often used to screen for early lung
cancer patients, but the problems of low sensitivities
and specificities exist[2] . Studies have shown that the
false positive rate of diagnosis is close to 50% upon use
of conventional methods for the detection of suspicious
nodules, and unnecessary invasive examination and
follow-up may grow accordingly as well[3] . miRNA is
a single-stranded non-coding RNA consisting of 2123 nt bases, whose direct complementary binding to the
target gene mRNA may lead to target mRNA molecular
degradation or translational inhibition, which as a result
decreases the expression of target genes, and in this
way miRNA participates in the process of proliferation,
differentiation, apoptosis, and cell death[4-6] . Compared
with the existing lung cancer test method, detection
of miRNA is expected to become a method for early
diagnosis. Recently, much research has been performed
regarding the effect of detection of circulating miRNA-
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21 on the early diagnosis of lung cancer in China and
abroad. Though the results showed varying degrees of
certainty, there were some limitations in the extensive
use of circulating miRNA-21 detection because sample
sizes of the independent research studies were too
small. Therefore, to scientifically evaluate the early
diagnostic value of miRNA-21 in diagnosing lung
cancer, we collected pertinent literature articles to
perform a meta-analysis. Based on the principle and
method of epidemiology, the articles that conformed
to the standard were evaluated and selected for
quantitative synthesis to get a comprehensive and
reliable result[7] .

the diagnostic test steps were detailed; (7) whether
patients with all kinds of lung cancer were included;
and (8) whether internal controls were used in the
process of testing. According to the above standards, we
classified the qualities of the research into five grades:
A, meets all quality standards; B, meets 7 standards;
C, meets 6 standards; D, meets 5 standards; E, meets 4
standards.

2

Heterogeneity test: Heterogeneity was analyzed using
Meta Disc 1.4 software. If there was no significance
in heterogeneity (P > 0.05), a fixed effects model
was chosen. If it was the opposite (P < 0.05), a
random effects model was chosen. The weighted
sensitivity, specificity, positive likelihood ratio and
negative likelihood ratio diagnostic advantage, and its
95% Confidence Interval (CI) were calculated using
Meta Disc 1.4 software, and also using the software the
SROC curve was analyzed to estimate the AUC.

2.1

Materials and Methods
Source of material

Databases such as Wan Fang, VIP, Pub Med, and
Elsevier were systematically searched from 2005
to 2013 to collect relevant references in which
the diagnostic value of circulating miRNA-21 in
lung cancer was evaluated. The English key words
for research were lung cancer and miRNA. The
Chinese key words were lung cancer, detection, and
miRNA. Supplement retrieval of the references in the
literature avoided the leak of some references by means
of network retrieval.
2.2

Standard of inclusion and exclusion

Inclusion criteria inlcude: (1) the diagnostic study
type; (2) the diagnosis value of circulating miRNA21 in lung cancer as a research theme; (3) patients
definitely diagnosed by the gold standard test; (4)
complete data extracted via the original material; and
(5) language limited to Chinese and English. Exclusion
criteria include: (1) literature as abstracts, lectures,
commentary, and review studies; (2) a sample size of
less than 40; (3) whole or part of the lung cancer
patients not confirmed using the gold standard method;
and (4) repeat reports, reports with small amount of
information, and literature that cannot be used.
2.3

Quality evaluation of the literature

Quality classification of the literature include: (1)
whether the gold standard method was set up; (2)
whether the gold standard test stayed independent of
the evaluation test; (3) whether the blind method was
used; (4) whether data was provided for calculating
sensitivity and specificity; (5) whether the right method
was chosen to determine the critical value; (6) whether

2.4

Data extraction

The author(s), published time, data, sample size, and
test method were extracted.
2.5

3
3.1

Statistical analysis of data

Results
Basic characteristics of the research

A total of 143 references from January 2005 to April
2013 were retrieved initially, and a total of 9 references
conformed to the inclusion criteria; one piece[8] was
ruled out because the sample size was less than 40,
leaving 8 references to be included at the end of
which 7 references[9-15] were in English and one was
in Chinese[16] . Two pieces of data were extracted from
Tang et al.[14] and one piece from the other 7 references;
as a result, 9 pieces of data including a total of 1040
subjects were ultimately analyzed. Basic characteristics
of the research are shown in Table 1.
3.2

Quality evaluation of the research

All research studies were based on the gold standard of
pathological diagnosis; independent in the evaluation
test, provided data for calculating sensitivity and
specificity, and described clear experimental steps. Six
studies used a correct method to determine the
critical value; the remaining 2 pieces lacked detailed
description. The experimental groups in 5 studies were
for lung cancer patients, the other 3 for non-small cell
lung cancer; internal control was used in the process of
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Table 1
Author
Shen et al.[9]
Shen et al.[10]
Wei et al.[11]
Zhang et al.[16]
Wang and Zhang[12]
Li et al.[13]
Tang et al.[14]
Tang et al.[14]
Abd-El-Fattah et al.[15]

Year Research design
2011 Diagnostic test
2011 Diagnostic test
2011 Diagnostic test
2012 Diagnostic test
2012 Diagnostic test
2012 Diagnostic test
2013 Diagnostic test
2013 Diagnostic test
2013 Diagnostic test
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Summary of included studies.

MicroRNA assay
Test Control TP
Real-time qRT- PCR
58
29
46
qRT- PCR
76
80
43
Real-time RT-PCR
63
30
48
Real-time RT-PCR 129
83
100
Real-time qRT- PCR
31
39
27
Real-time qRT- PCR
82
50
39
Real-time qRT- PCR
62
60
30
Real-time qRT- PCR
34
32
18
Real-time qRT- PCR
65
37
56

FP FN TN Specimen Quadas
10 12 19
1
E
29 33 51
1
D
9 15 21
1
D
12 29 71
2
D
10
4 29
2
D
6 43 44
2
D
13 32 47
1
E
9 16 23
1
E
5
9 32
2
C

testing in 3 articles, while the rest did not use or did not
mention it; whether blind method was used is not clear
in the references. The quality evaluation results for the
research are shown in Table 1.
3.3

Basic data in the studies

The 9 pieces of data obtained from the 8 articles, types
of samples, and the original data extracted are shown in
Table 1.
3.4

Meta analysis of combined statistics

The Spearman correlation coefficient of logarithm
of sensitivity and specificity was 0.133, P D 0:732,
showing that there was no threshold effect. The Cochran
Q value of Diagnostic Odds Ratio (DOR) was 36.25,
P D 0:0000; suggesting the presence of no threshold
effect. Because there was significance in heterogeneity
(P < 0.05), we chose a random effects model. For the
9 pieces of data, the weighted sensitivity was 0.68 (95%
CI 0.64-0.72), specificity 0.77 (95% CI 0.72-0.80),
Positive Likelihood Ratio (PLR) 2.84 (95% CI 2.033.96), Negative Likelihood Ratio (NLR) 0.40 (95% CI
0.29-0.56), and SROC AUC was 0.8133, as shown in
Fig. 1.
3.5

Meta regression analysis

Meta-analysis results of the combined 9 pieces of
data showed heterogeneity among the various research
studies caused by the non-threshold effect. The
results of exploring the sources of heterogeneity by
meta-regression analysis showed for sample factors
P D 0:0029; which means that the heterogeneity was
related to the sample.
3.6

Subgroup analysis

The 9 pieces of data were divided into 2 groups: A,
plasma group, and B, serum group. For plasma group,
the weighted sensitivity was 0.63 (95% CI 0.57-0.69),

Fig. 1 SROC curve of circulating miRNA-21 for the
diagnosis of lung cancer. The size of each solid circle
represents the size of each study in the meta-analysis. The
regression SROC curve indicates the overall diagnostic
accuracy.

specificity 0.70 (95% CI 0.63-0.76), PLR 1.95 (95%
CI 1.57-2.4), NLR 0.53 (95% CI 0.40-0.7), and AUC
0.7318. For the serum group, the indices mentioned
above were 0.72 (95% CI 0.67-0.77), 0.84 (95% CI
0.79-0.89), 4.50 (95% CI 3.28-6.18), 0.27 (95% CI
0.13-0.57), and AUC 0.8987. Sensitivity and specificity
of the serum group were higher than those of the plasma
group, and AUC was larger for the serum group. All
these indicated that in lung cancer the early diagnostic
value of miRNA-21 in serum was better than the value
in plasma.
3.7

Publication bias analysis

Funnel plot analysis of publication bias (Fig. 2) of
this analytical study of the early diagnostic value of
circulating miRNA-21 in lung cancer showed P D
0:94; prompting a low likelihood of publication bias.
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Fig. 2 Funnel plot. The statistically nonsignificant p-value
of 0.94 for the slope coefficient suggests symmetry in the data
and a low likelihood of publication bias.

4

Conclusions

The results of this study showed that in diagnosis of
lung cancer with circulating miRNA-21, the weighted
sensitivity was 0.68, suggesting that the rate of missed
diagnosis was 0.32, and the weighted specificity
was 0.77, prompting that the missed diagnosis rate
was 0.23. The likelihood ratio is a compound index
reflecting both sensitivity and specificity. Research
has shown that when PLR > 10 and NLR < 0.1, the
likelihood ratio has a convincing diagnostic effect, and
when PLR > 5 and NLR < 0.2, it has strong diagnostic
efficacy[17] . In this study, the combined PLR was 2.84,
indicating that by detection of circulating miRNA-21
in patients with lung cancer, the opportunity of positive
results was 2.84 times more than that in normal persons;
the combined NLR was 0.40, showing through this test
that the frequency of a false negative judgment was 0.4
times more than that of a correct judgment. Furthermore
the size of SROC AUC can be calculated to display
the accuracy level of the diagnostic test[17] . A certain
degree of value could be certified in early diagnosis of
lung cancer with circulating miRNA-21 when AUC =
0.8133. The subgroup analysis of the samples, for the
early diagnostic value of miRNA-21 in serum, showed
that the weighted sensitivity was 0.72, specificity 0.84,
PLR 4.50, NLR 0.27, and AUC 0.8987. While for
the early diagnostic value of miRNA-21 in plasma,
the 5 indices mentioned above were 0.63, 0.70, 1.95,
0.53, and 0.7318, respectively. Comparison between
the two groups illustrated that in lung cancer the early
diagnostic value of miRNA-21 in the serum was better
than the value in plasma.
Baseline similarity of the pertinent literature was
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good. The funnel plot indicated an imminent possibility
of publication bias. And by subgroup analysis, the
research showed that in lung cancer the early diagnostic
value of miRNA-21 in the serum was better than that
in the plasma. But the research still had the following
problems: (1) the majority of the included papers did
not use the blind method, leading to a measurement
bias; (2) the languages of the papers were Chinese
and English, which could not exclude the possibility
of a language bias. More large-sample and doubleblind statistical tests will be needed in the future to
increase the accuracy of using miRNA-21 in early
diagnosis of lung cancer. In the experiment by Shen
et al.[9] , by combining detection of miR-21, miR126, miR-486-5p, and miR-210 in plasma for early
diagnosis of Non-Small Cell Lung Cancer (NSCLC),
the sensitivity was 0.86 and specificity 0.96. Chen
et al.[18] drew the conclusion that the sensitivity and
specificity of 10 serum miRNA combined detection
in the early diagnosis of NSCLC reached 0.92 and
0.90, respectively. So we should focus on exploring
circulating miRNAs whose expression changes are
significant in lung cancer, and then through detections
of multiple miRNAs or combination with other tests
such as X-ray and CT, the sensitivity and specificity of
early diagnosis of lung cancer will improve to a certain
degree. Under these circumstances, early detection and
early treatment will improve the survival rate of patients
with lung cancer.
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